[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100617782":3},{"organization":4,"outcomesModule":7,"designInfo":19,"detailedDescription":11,"studyPopulation":11,"armGroups":29,"interventions":50,"overallOfficials":11,"centralContacts":64,"locations":70,"responsibleParty":159,"collaborators":11,"id":161,"slug":11,"hasResults":162,"nctId":163,"briefTitle":164,"officialTitle":165,"acronym":11,"eligibilityCriteria":166,"healthyVolunteers":162,"sex":167,"minAge":168,"maxAge":169,"enrollmentInfo":170,"targetDuration":11,"studyType":173,"phases":174,"briefSummary":176,"conditions":177,"keywords":11,"overallStatus":179,"whyStopped":11,"lastUpdateSubmitDate":180,"lastUpdatePostDateStruct":181,"startDateStruct":184,"completionDateStruct":186,"leadSponsor":188,"locationsCount":189},{"fullName":5,"class":6},"Atom Therapeutics Co., Ltd","INDUSTRY",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":11},[9],{"measure":10,"description":11,"timeFrame":12},"The change in the urine albumin-to-creatinine ratio (mg\u002Fg) as reported in the laboratory report compared to the baseline",null,"Week 40",[14,16],{"measure":10,"description":11,"timeFrame":15},"Week 16",{"measure":17,"description":18,"timeFrame":12},"Incidence of treatment-emergent adverse events (Safety and Tolerability)","Incidence of treatment-emergent adverse events (TEAEs), including AEs of special interest (AESIs), serious AEs (SAEs), and AEs leading to study treatment discontinuation",{"allocation":20,"interventionModel":21,"interventionModelDescription":11,"primaryPurpose":22,"observationalModel":11,"timePerspective":11,"maskingInfo":23},"RANDOMIZED","PARALLEL","TREATMENT",{"masking":24,"maskingDescription":11,"whoMasked":25},"TRIPLE",[26,27,28],"PARTICIPANT","CARE_PROVIDER","INVESTIGATOR",[30,36,40,45],{"label":31,"type":32,"description":33,"interventionNames":34},"ABP-671 plus febuxostat Group 1","ACTIVE_COMPARATOR","Investigators may consider the use of urine alkalinizing agents on an as-needed basis according to the subject's specific condition and standard clinical practice",[35],"Drug: ABP-671 plus febuxostat Group 1",{"label":37,"type":32,"description":33,"interventionNames":38},"ABP-671 plus febuxostat Group 2",[39],"Drug: ABP-671 plus febuxostat Group 2",{"label":41,"type":42,"description":33,"interventionNames":43},"ABP-671 Group","EXPERIMENTAL",[44],"Drug: ABP-671 Group",{"label":46,"type":47,"description":33,"interventionNames":48},"Placebo Group","PLACEBO_COMPARATOR",[49],"Drug: Placebo Group",[51,55,58,61],{"type":52,"name":31,"description":53,"armGroupLabels":54,"otherNames":11},"DRUG","ABP-671 Dose 1 + Febuxostat Dose 1-tablets(PO)",[31],{"type":52,"name":37,"description":56,"armGroupLabels":57,"otherNames":11},"ABP-671 Dose 2 + Febuxostat Dose 2-tablets(PO)",[37],{"type":52,"name":41,"description":59,"armGroupLabels":60,"otherNames":11},"ABP-671 Dose 2 + Febuxostat placebo-tablets(PO)",[41],{"type":52,"name":46,"description":62,"armGroupLabels":63,"otherNames":11},"ABP-671 placebo-tablets(PO) + Febuxostat placebo-tablets(PO)",[46],[65],{"name":66,"role":67,"phone":68,"phoneExt":11,"email":69},"Renbo Gao","CONTACT","+86 15062305252","renbo.gao@atombp.com",[71,84,93,102,114,119,124,134,144,154],{"facility":72,"status":11,"city":73,"state":74,"zip":75,"country":76,"countryCode":77,"cosmosGeoPoint":78,"geoPoint":83,"contacts":11},"Renal Research Gosford Pty Ltd","Gosford","New South Wales","2250","Australia","AU",{"type":79,"coordinates":80},"Point",[81,82],151.34399,-33.4244,{"lat":82,"lon":81},{"facility":85,"status":11,"city":86,"state":74,"zip":87,"country":76,"countryCode":77,"cosmosGeoPoint":88,"geoPoint":92,"contacts":11},"Genesis Research services","Newcastle","2019",{"type":79,"coordinates":89},[90,91],151.7801,-32.92953,{"lat":91,"lon":90},{"facility":94,"status":11,"city":95,"state":96,"zip":11,"country":76,"countryCode":77,"cosmosGeoPoint":97,"geoPoint":101,"contacts":11},"Paratus Clinical Research Brisbane","Brisbane","Queensland",{"type":79,"coordinates":98},[99,100],153.02809,-27.46794,{"lat":100,"lon":99},{"facility":103,"status":11,"city":104,"state":105,"zip":106,"country":107,"countryCode":108,"cosmosGeoPoint":109,"geoPoint":113,"contacts":11},"Beijing Tsinghua Changgung Hospital","Beijing","Beijing Municipality","100000","China","CN",{"type":79,"coordinates":110},[111,112],116.39723,39.9075,{"lat":112,"lon":111},{"facility":115,"status":11,"city":104,"state":105,"zip":106,"country":107,"countryCode":108,"cosmosGeoPoint":116,"geoPoint":118,"contacts":11},"Peking University First Hospital",{"type":79,"coordinates":117},[111,112],{"lat":112,"lon":111},{"facility":120,"status":11,"city":104,"state":105,"zip":106,"country":107,"countryCode":108,"cosmosGeoPoint":121,"geoPoint":123,"contacts":11},"Xuanwu Hospital Capital Medical University",{"type":79,"coordinates":122},[111,112],{"lat":112,"lon":111},{"facility":125,"status":11,"city":126,"state":127,"zip":128,"country":107,"countryCode":108,"cosmosGeoPoint":129,"geoPoint":133,"contacts":11},"Jiangsu Province Hospital","Nanjing","Jiangsu","210000",{"type":79,"coordinates":130},[131,132],118.77778,32.06167,{"lat":132,"lon":131},{"facility":135,"status":11,"city":136,"state":137,"zip":138,"country":107,"countryCode":108,"cosmosGeoPoint":139,"geoPoint":143,"contacts":11},"Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine","Shanghai","Shanghai Municipality","200000",{"type":79,"coordinates":140},[141,142],121.45806,31.22222,{"lat":142,"lon":141},{"facility":145,"status":11,"city":146,"state":147,"zip":148,"country":107,"countryCode":108,"cosmosGeoPoint":149,"geoPoint":153,"contacts":11},"Sir Run Run Shaw Hospital , affiliated with the Zhejiang University School of Medicine","Hangzhou","Zhejiang","310000",{"type":79,"coordinates":150},[151,152],120.16142,30.29365,{"lat":152,"lon":151},{"facility":155,"status":11,"city":146,"state":147,"zip":148,"country":107,"countryCode":108,"cosmosGeoPoint":156,"geoPoint":158,"contacts":11},"Zhejiang Provincial People's Hospital",{"type":79,"coordinates":157},[151,152],{"lat":152,"lon":151},{"type":160,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100617782",false,"NCT07323095","Evaluate the Efficacy and Safety of ABP-671 in Subjects With Chronic Kidney Disease and Hyperuricaemia","A Phase 2, International, Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy and Safety of ABP-671 in Subjects With Chronic Kidney Disease and Hyperuricaemia","Inclusion Criteria:\n\n* Male or female aged 18-75 years , who voluntarily participate in this clinical trial, understand and comply with the procedures stipulated in this study\n* Patients who have been diagnosed with CKD based on Clinical Practice Guideline\n* During screening, body mass index (BMI) was ≥18.0 and ≤ 40.0 kg\u002Fm2\n* The sUA levels \\> 420 μmol\u002FL (7.0 mg\u002FdL)\n\nExclusion Criteria:\n\n* History of renal transplantation\n* The 24-hour urinary protein ≥ 3.5 g\u002Fday\n* Liver function abnormality: aspartate aminotransferase or alanine aminotransferase, or alkaline phosphatase \\> 3 times the upper limit of normal value (ULN)\n* Subjects with mental disorders who are unable to communicate normally with the investigator\n* Subjects who have participated in another clinical study during the screening period are within 30 days of the last dose of the study drug in another study\n* The investigator judged that the subject was not suitable for participation in this study","ALL","18 Years","75 Years",{"count":171,"type":172},80,"ESTIMATED","INTERVENTIONAL",[175],"PHASE2","This is a phase 2, international, multicenter, randomized, double blind, placebo-controlled trial to evaluate the efficacy and safety of ABP-671 in subjects with CKD and hyperuricaemia, to preliminarily evaluate the efficacy of ABP-671 in the treatment of subjects with CKD and hyperuricemia, primary Efficacy Endpoint is change in UACR from baseline to Week 40",[178],"Chronic Kidney Disease","NOT_YET_RECRUITING","2026-06-03",{"date":182,"type":183},"2026-06-04","ACTUAL",{"date":185,"type":172},"2026-06-30",{"date":187,"type":172},"2028-01-31",{"name":5,"class":6},10]